No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Read This Before Considering Hunan Fangsheng Pharmaceutical Co., Ltd. (SHSE:603998) For Its Upcoming CN¥0.06 Dividend
Overview of the lifting of restrictions on the trading of A shares | February 27.
According to Zhito Finance APP, on February 27, a total of 5 listed companies had their restricted stocks lifted, with a total market value of approximately 64.4634 million yuan. The specific details of the restricted stock release today are as follows: Stock Abbreviation Stock Code Restricted Stock Type Released Shares Zhejiang Dun'an Artificial Environment 002011 Stock-based Incentive 3.5237 million PNC Process Systems 603690 Stock-based Incentive 0.162 million Hunan Fangsheng Pharmaceutical 603998 Stock-based Incentive 0.4367 million GuiZhou YongJi Printing 603058 Stock-based Incentive 1.051 million Zhongyin Babi Food 605338 Stock-based Incentive 0.0815 million
Hunan Fangsheng Pharmaceutical Acquires Licensing for Xiaoqinglong Capsules
Hunan Fangsheng Pharmaceutical (603998.SH) special dividend distribution for 2024: 0.06 yuan per share, with stock registration on March 4.
Hunan Fangsheng Pharmaceutical (603998.SH) announced the special dividend distribution for 2024, and this profit distribution is based on Fang...
Hunan Fangsheng Pharmaceutical (603998.SH): Acquired the marketing authorization for Pharmaceutical.
On February 25, GeLongHui reported that Hunan Fangsheng Pharmaceutical (603998.SH) announced that on February 25, 2025, the company signed a "Pharmaceutical Listing License Transfer Agreement" with Chengdu Nuodikan Biopharmaceutical Co., Ltd. (hereinafter referred to as "Nuodikan Bio"). The company decided to acquire the listing license for the "Xiao Qing Long Capsules" (including but not limited to the ownership of the pharmaceutical prescription, production process, technical secrets, patents related to the symbol, technical data, and other data). Xiao Qing Long Capsules have the effects of relieving exterior condition and treating cough and asthma. It is used for wind-cold water retention, aversion to cold and fever, no sweating, and coughing with thin phlegm.
Investors Don't See Light At End Of Hunan Fangsheng Pharmaceutical Co., Ltd.'s (SHSE:603998) Tunnel And Push Stock Down 29%